{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:35:36Z","timestamp":1787495736727,"version":"build-2736575974"},"reference-count":97,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Inflammatory bowel disease (IBD) is associated with an increased risk of venous thromboembolic events (VTEs) and a moderate risk of arterial cardiovascular events. This varies with inflammatory activity and acute-care exposure, with pathophysiological data supporting a thromboinflammatory phenotype in which intestinal inflammation influences systemic vascular homeostasis through innate immune activation, coagulation\u2013platelet crosstalk, endothelial dysfunction, impaired fibrinolysis, and immunothrombosis. Clinically, prevention and management should be integrated into routine care and anchored in sustained, steroid-sparing disease control, combined with guideline-based in-hospital thromboprophylaxis and standard cardiovascular prevention. Decisions regarding anticoagulant therapy after VTEs should follow established principles while recognizing that recurrence prevention depends not only on anticoagulant choice but also on minimizing repeated inflammatory and treatment-related risk exposures. Cardiovascular risk assessment and optimization of modifiable factors should be considered before therapy escalation or treatment switching. Future advances will likely come from more personalized risk assessment across dynamic high-risk windows and from adjunctive, mechanism-informed strategies targeting key nodes of the gut\u2013vascular interface and immunothrombosis.<\/jats:p>","DOI":"10.3390\/medicina62020270","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:41:56Z","timestamp":1769528516000},"page":"270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["From Inflammation to Thrombosis: The Prothrombotic State and Cardiovascular Risk in Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-8962","authenticated-orcid":false,"given":"Vlad Dumitru","family":"Brata","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Regional Institute of Gastroenterology and Hepatology \u201cProf. Dr. Octavian Fodor\u201d, 400394 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-9670","authenticated-orcid":false,"given":"Dana Alina","family":"Crisan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"},{"name":"Clinical Municipal Hospital, 400139 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-2291","authenticated-orcid":false,"given":"Angela","family":"Cozma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 4th Medical Discipline, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4090-0164","authenticated-orcid":false,"given":"Cezara-Andreea","family":"Gerdanovics","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 4th Medical Discipline, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5508-2598","authenticated-orcid":false,"given":"Stefan Lucian","family":"Popa","sequence":"additional","affiliation":[{"name":"Second Medical Department, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mircea Vasile","family":"Milaciu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 4th Medical Discipline, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-142X","authenticated-orcid":false,"given":"Olga Hilda","family":"Or\u0103\u0219an","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 4th Medical Discipline, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400015 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: Cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11894-019-0705-6","article-title":"Evolving Epidemiology of IBD","volume":"21","author":"Windsor","year":"2019","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","article-title":"Immunological pathogenesis of inflammatory bowel disease","volume":"16","author":"Lee","year":"2018","journal-title":"Intest. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41575-021-00492-8","article-title":"International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease","volume":"18","author":"Olivera","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/apt.12294","article-title":"Meta-analysis: The risk of venous thromboembolism in patients with inflammatory bowel disease","volume":"37","author":"Yuhara","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/asheducation-2016.1.180","article-title":"Thrombosis in the setting of obesity or inflammatory bowel disease","volume":"2016","author":"Lentz","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: A cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, H., Xu, M., Hao, H., Hill, M.A., Xu, C., and Liu, Z. (2022). Endothelial Dysfunction and Arterial Stiffness in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113179"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/00365521.2025.2488053","article-title":"Adult-onset inflammatory bowel disease and the risk of venous thromboembolism\u2014A Swedish nationwide cohort study 2007\u20132021","volume":"60","author":"Forss","year":"2025","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41598-021-81657-y","article-title":"Risk of venous thromboembolism in Asian patients with inflammatory bowel disease: A nationwide cohort study","volume":"11","author":"Heo","year":"2021","journal-title":"Sci Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.14309\/ajg.0000000000001237","article-title":"Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study","volume":"116","author":"Bernstein","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/gut.2010.228585","article-title":"Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: A population-based nationwide study","volume":"60","author":"Kappelman","year":"2011","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhang, H., and Wang, X. (2021). Risk Factors of Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.693927"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1053\/j.gastro.2010.05.026","article-title":"Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism","volume":"139","author":"Novacek","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/ibd\/izaf078","article-title":"Risk Factors for Venous Thromboembolism in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis by Phase of Care","volume":"31","author":"Gozdzik","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kristensen, S.L., Ahlehoff, O., Lindhardsen, J., Erichsen, R., Jensen, G.V., Torp-Pedersen, C., Nielsen, O.H., Gislason, G.H., and Hansen, P.R. (2013). Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death\u2014A Danish nationwide cohort study. PLoS ONE, 8.","DOI":"10.1371\/annotation\/b4a49855-87b9-436a-a4bd-bc64b50a6c93"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/europace\/eut312","article-title":"Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: A nationwide study","volume":"16","author":"Kristensen","year":"2014","journal-title":"Europace"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ecco-jcc\/jjx162","article-title":"Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis","volume":"12","author":"Sarlos","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MCG.0000000000000408","article-title":"Antitumor Necrosis Factor-\u03b1 Therapy Is Associated with Reduced Risk of Thromboembolic Events in Hospitalized Patients with Inflammatory Bowel Disease","volume":"50","author":"deFonseka","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cgh.2014.07.017","article-title":"Increased risk of venous thromboembolic events with corticosteroid vs. biologic therapy for inflammatory bowel disease","volume":"13","author":"Higgins","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjh.17388","article-title":"Glucocorticoid use and risk of first and recurrent venous thromboembolism: Self-controlled case-series and cohort study","volume":"193","author":"Orsi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1572-0241.2006.00943.x","article-title":"Inflammation and coagulation in inflammatory bowel disease: The clot thickens","volume":"102","author":"Danese","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"189341","DOI":"10.1155\/2015\/189341","article-title":"Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function","volume":"2015","author":"Pastorelli","year":"2015","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ali, F., Li, D., Su, Y., Chen, L., Cheng, X., Zheng, X., and Mao, J. (2025). Bio-Active Peptides from Marine Sources: Mechanistic Insights into Immune Regulation, Microbiota Modulation, and Intestinal Barrier Protection. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110508"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41569-022-00737-2","article-title":"Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease","volume":"20","author":"Violi","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2023.11.005","article-title":"Gut dysbiosis-related thrombosis in inflammatory bowel disease: Potential disease mechanisms and emerging therapeutic strategies","volume":"232","author":"Papa","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","article-title":"Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk","volume":"165","author":"Zhu","year":"2016","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wang, S., Ni, Y., Zhou, S., Peng, H., Cao, Y., Zhu, Y., Gong, J., Lu, Q., Han, Z., and Lin, Y. (2025). Effects of choline metabolite-trimethylamine N-oxide on immunometabolism in inflammatory bowel disease. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1591151"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.vph.2014.05.005","article-title":"Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player","volume":"62","author":"Bode","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.crohns.2012.05.016","article-title":"Tissue factor exposing microparticles in inflammatory bowel disease","volume":"7","author":"Palkovits","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1038\/s41467-025-57001-7","article-title":"Tissue factor-dependent colitogenic CD4+ T cell thrombogenicity is regulated by activated protein C signalling","volume":"16","author":"Leon","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1055\/s-0035-1556590","article-title":"Hypercoagulability and Platelet Abnormalities in Inflammatory Bowel Disease","volume":"41","author":"Senchenkova","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3904\/kjim.2025.118","article-title":"Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease","volume":"40","author":"Kim","year":"2025","journal-title":"Korean J. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCGENETICS.113.000398","article-title":"Toll-like receptor 4 regulates platelet function and contributes to coagulation abnormality and organ injury in hemorrhagic shock and resuscitation","volume":"7","author":"Ding","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/MEG.0b013e3282faa759","article-title":"Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease","volume":"20","author":"Koutroubakis","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_38","first-page":"169","article-title":"The Paradox of NET Involvement in the Pathogenesis of Inflammatory Bowel Disease","volume":"32","author":"Morad","year":"2025","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"37252","DOI":"10.1038\/srep37252","article-title":"Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injury","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Pieterse, E., Rother, N., Yanginlar, C., Hilbrands, L.B., and van der Vlag, J. (2016). Neutrophils Discriminate between Lipopolysaccharides of Different Bacterial Sources and Selectively Release Neutrophil Extracellular Traps. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00484"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"jjaf078","DOI":"10.1093\/ecco-jcc\/jjaf078","article-title":"Association between inflammatory bowel disease, current therapies, and cardiovascular events: A review and meta-analysis of data from 2.2 million individuals","volume":"19","author":"Thomas","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehae338","article-title":"Risk of heart failure in inflammatory bowel disease: A Swedish population-based study","volume":"45","author":"Sun","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sun, J., Roelstraete, B., Svennberg, E., Halfvarson, J., Sundstr\u00f6m, J., Forss, A., Ol\u00e9n, O., and Ludvigsson, J.F. (2023). Long-term risk of arrhythmias in patients with inflammatory bowel disease: A population-based, sibling-controlled cohort study. PLoS Med., 20.","DOI":"10.1371\/journal.pmed.1004305"},{"key":"ref_45","first-page":"101456","article-title":"Association between inflammatory bowel disease and atrial fibrillation: A systematic review and meta-analysis","volume":"53","author":"Goyal","year":"2024","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/MEG.0000000000002562","article-title":"Inflammatory bowel disease and atrial fibrillation: A contemporary overview","volume":"35","author":"Konstantinou","year":"2023","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/sjg.sjg_622_20","article-title":"Is there any link between atrial arrhythmias and inflammatory bowel disease?","volume":"27","author":"Can","year":"2021","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e005892","DOI":"10.1161\/JAHA.117.005892","article-title":"Inflammatory bowel disease and risk of ischemic heart disease: An updated meta-analysis of cohort studies","volume":"6","author":"Feng","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjmed.2021.02.029","article-title":"Premature atherosclerotic cardiovascular disease risk among patients with inflammatory bowel disease","volume":"134","author":"Lee","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.114.009990","article-title":"Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: A population-based cohort study","volume":"130","author":"Dregan","year":"2014","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ejim.2014.05.009","article-title":"Inflammatory bowel diseases increase future ischemic stroke risk: A Taiwanese population-based retrospective cohort study","volume":"25","author":"Huang","year":"2014","journal-title":"Eur. J. Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Luo, C., Liu, L., Zhu, D., Ge, Z., Chen, Y., and Chen, F. (2025). Risk of stroke in patients with inflammatory bowel disease: A systematic review and meta-analysis. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03702-8"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2381","DOI":"10.1097\/MD.0000000000002381","article-title":"Inflammatory bowel disease increases the risk of peripheral arterial disease: A nationwide cohort study","volume":"94","author":"Lin","year":"2015","journal-title":"Medicine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/ecco-jcc\/jjad193","article-title":"Anti-tumor Necrosis Factor Alpha versus corticosteroids: A 3-fold difference in the occurrence of venous thromboembolism in inflammatory bowel disease\u2014A systematic review and meta-analysis","volume":"18","author":"Rancz","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2036.2000.00824.x","article-title":"Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease","volume":"14","author":"Carty","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","article-title":"Risk of ischaemic heart disease in patients with inflammatory bowel disease: A nationwide Danish cohort study","volume":"62","author":"Rungoe","year":"2013","journal-title":"Gut"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1210\/jc.2017-01133","article-title":"Associations between systemic and local corticosteroid use with metabolic syndrome and body mass index","volume":"102","author":"Savas","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_60","first-page":"55","article-title":"Effects of immunosuppressive drugs on platelet aggregation in vitro","volume":"7","author":"Takada","year":"2002","journal-title":"Ann. Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_62","first-page":"981","article-title":"Tolerability profile of thiopurines in inflammatory bowel disease: A prospective experience","volume":"52","author":"Macaluso","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cgh.2012.12.026","article-title":"Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn\u2019s disease","volume":"11","author":"Seinen","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/MIB.0000000000000301","article-title":"Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: A prospective study","volume":"21","author":"Bollen","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","article-title":"Vedolizumab for ulcerative colitis: Treatment outcomes from the VICTORY consortium","volume":"113","author":"Narula","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejim.2019.06.006","article-title":"Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers","volume":"66","author":"Tursi","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Nishida, Y., Hosomi, S., Fujimoto, K., Kobayashi, Y., Nakata, R., Maruyama, H., Ominami, M., Nadatani, Y., Fukunaga, S., and Otani, K. (2025). Thromboembolic Risk in Ulcerative Colitis Patients on Advanced Therapy: A Real-World Data Analysis. Inflamm. Bowel Dis., izaf302.","DOI":"10.1093\/ibd\/izaf302"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Louis, E., Sebastian, S., Siegmund, B., Bossuyt, P., Danese, S., de Boer, N., Loftus, E.V., Moum, B., Peyrin-Biroulet, L., and Schreiber, S. (Clin. Gastroenterol. Hepatol., 2025). Long-Term Safety of Vedolizumab in Patients with Ulcerative Colitis\/Crohn\u2019s Disease: A Prospective Observational Study, Clin. Gastroenterol. Hepatol., in press.","DOI":"10.1016\/j.cgh.2025.10.006"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e2234200","DOI":"10.1001\/jamanetworkopen.2022.34200","article-title":"Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults with Inflammatory Bowel Diseases","volume":"5","author":"Singh","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40272-025-00717-2","article-title":"Vedolizumab versus other biologics and the risk of venous thromboembolism in patients with pediatric-onset inflammatory bowel diseases: A target trial emulation study","volume":"27","author":"Tsai","year":"2025","journal-title":"Paediatr. Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of ustekinumab in inflammatory bowel disease: Pooled safety analysis through 5 years in Crohn\u2019s disease and 4 years in ulcerative colitis","volume":"18","author":"Ghosh","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_73","unstructured":"Center for Drug Evaluation Research (2025, September 05). FDA Approves Boxed Warning about Increased Risk of Blood Clots Death with Higher Dose of Arthritis Ulcerative Colitis Medicine Tofacitinib (Xeljanz Xeljanz XR), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_75","unstructured":"European Commission (2026, January 14). Anexa I: Rezumatul Caracteristicilor Produsului [Annex I: Summary of Product Characteristics] (XELJANZ). Community Register of Medicinal Products for Human Use. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20211115153854\/anx_153854_ro.pdf."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2455536","DOI":"10.1080\/07853890.2025.2455536","article-title":"Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: A systematic review and network meta-analysis","volume":"57","author":"Yang","year":"2025","journal-title":"Ann Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1389450121666200902164240","article-title":"Thrombosis in IBD in the era of JAK inhibition","volume":"22","author":"Solitano","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"102056","DOI":"10.1016\/j.bpg.2025.102056","article-title":"Atherosclerotic cardiovascular disease and inflammatory bowel disease: Epidemiology, pathogenesis and risk assessment","volume":"78","author":"Puca","year":"2025","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Gala, D., Newsome, T., Roberson, N., Lee, S.M., Thekkanal, M., Shah, M., Kumar, V., Bandaru, P., and Gayam, V. (2022). Thromboembolic events in patients with inflammatory bowel disease: A comprehensive overview. Diseases, 10.","DOI":"10.3390\/diseases10040073"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO Guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"ref_83","first-page":"502314","article-title":"Spanish Working Group in Crohn\u2019s Disease and Ulcerative Colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease","volume":"48","author":"Carpio","year":"2025","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/jgh.14472","article-title":"Comparison of a novel predictor of venous thromboembolic complications in inflammatory bowel disease with current predictors","volume":"34","author":"Ohta","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/MIB.0b013e3182802a65","article-title":"The utility of screening for asymptomatic lower extremity deep venous thrombosis during inflammatory bowel disease flares: A pilot study","volume":"19","author":"Nguyen","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3748\/wjg.v29.i3.508","article-title":"Artificial intelligence and inflammatory bowel disease: Where are we going?","volume":"29","author":"Spadaccini","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e016223","DOI":"10.1161\/JAHA.119.016223","article-title":"Nonlethal inhibition of gut microbial trimethylamine N-oxide production improves cardiac function and remodeling in a murine model of heart failure","volume":"9","author":"Organ","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41598-020-80063-0","article-title":"Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12664-020-01114-y","article-title":"Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation","volume":"40","author":"Tam","year":"2021","journal-title":"Indian J. Gastroenterol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jtha.2024.11.028","article-title":"Therapeutic potential of DNases in immunothrombosis: Promising succor or uncertain future?","volume":"23","author":"Zalghout","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/BSR20253205","article-title":"The PAD4 inhibitor GSK484 diminishes neutrophil extracellular trap in the colon mucosa but fails to improve inflammatory biomarkers in experimental colitis","volume":"45","author":"Xie","year":"2025","journal-title":"Biosci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Tettoni, E., Gabbiadini, R., Dal Buono, A., Privitera, G., Vadal\u00e0, V., Migliorisi, G., Bertoli, P., Quadarella, A., Bezzio, C., and Armuzzi, A. (2025). TL1A as a target in inflammatory bowel disease: Exploring mechanisms and therapeutic potential. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115017"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/mi.2012.124","article-title":"TL1A\/TNFSF15 directly induces proinflammatory cytokines, including TNF\u03b1, from CD3+CD161+ T cells to exacerbate gut inflammation","volume":"6","author":"Jin","year":"2013","journal-title":"Mucosal Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40259-025-00706-4","article-title":"TL1A inhibition in inflammatory bowel disease: A pipeline review","volume":"39","author":"Solitano","year":"2025","journal-title":"BioDrugs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 trial of anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S2468-1253(25)00129-3","article-title":"Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): A multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial","volume":"10","author":"Danese","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Petronio, L., Dal Buono, A., Gabbiadini, R., Migliorisi, G., Privitera, G., Ferraris, M., Loy, L., Bezzio, C., and Armuzzi, A. (2025). Drug Development in Inflammatory Bowel Diseases: What Is Next?. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020190"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:11:21Z","timestamp":1769530281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":97,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["medicina62020270"],"URL":"https:\/\/doi.org\/10.3390\/medicina62020270","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}